BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1377690)

  • 1. The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the "b"domain of C9.
    Ninomiya H; Sims PJ
    J Biol Chem; 1992 Jul; 267(19):13675-80. PubMed ID: 1377690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identity of a peptide domain of human C9 that is bound by the cell-surface complement inhibitor, CD59.
    Chang CP; Hüsler T; Zhao J; Wiedmer T; Sims PJ
    J Biol Chem; 1994 Oct; 269(42):26424-30. PubMed ID: 7523406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
    Tschopp J; Chonn A; Hertig S; French LE
    J Immunol; 1993 Aug; 151(4):2159-65. PubMed ID: 8345200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
    Rollins SA; Zhao J; Ninomiya H; Sims PJ
    J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of human and rat CD59 to the terminal complement complexes.
    Lehto T; Morgan BP; Meri S
    Immunology; 1997 Jan; 90(1):121-8. PubMed ID: 9038722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identity of the segment of human complement C8 recognized by complement regulatory protein CD59.
    Lockert DH; Kaufman KM; Chang CP; Hüsler T; Sodetz JM; Sims PJ
    J Biol Chem; 1995 Aug; 270(34):19723-8. PubMed ID: 7544344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
    Lehto T; Meri S
    J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
    Tomlinson S; Whitlow MB; Nussenzweig V
    J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement pores in erythrocyte membranes. Analysis of C8/C9 binding required for functional membrane damage.
    Sims PJ
    Biochim Biophys Acta; 1983 Aug; 732(3):541-52. PubMed ID: 6871214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of the association of the eighth and ninth components of human complement within the membrane-bound cytolytic complex.
    Monahan JB; Stewart JL; Sodetz JM
    J Biol Chem; 1983 Apr; 258(8):5056-62. PubMed ID: 6833292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
    Rollins SA; Sims PJ
    J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of rabbit complement component C8. Functional evidence for the species-selective recognition of C8 alpha by homologous restriction factor (CD59).
    White RV; Kaufman KM; Letson CS; Platteborze PL; Sodetz JM
    J Immunol; 1994 Mar; 152(5):2501-8. PubMed ID: 7510745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeras of human complement C9 reveal the site recognized by complement regulatory protein CD59.
    Hüsler T; Lockert DH; Kaufman KM; Sodetz JM; Sims PJ
    J Biol Chem; 1995 Feb; 270(8):3483-6. PubMed ID: 7533152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of the ratio of the eighth and ninth components of human complement on complement-lysed membranes.
    Stewart JL; Monahan JB; Brickner A; Sodetz JM
    Biochemistry; 1984 Aug; 23(18):4016-22. PubMed ID: 6487588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule.
    Pausa M; Pellis V; Cinco M; Giulianini PG; Presani G; Perticarari S; Murgia R; Tedesco F
    J Immunol; 2003 Mar; 170(6):3214-22. PubMed ID: 12626580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity.
    Ninomiya H; Stewart BH; Rollins SA; Zhao J; Bothwell AL; Sims PJ
    J Biol Chem; 1992 Apr; 267(12):8404-10. PubMed ID: 1373727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities.
    Tschopp J; Masson D; Schäfer S; Peitsch M; Preissner KT
    Biochemistry; 1988 May; 27(11):4103-9. PubMed ID: 2458130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous restriction factor: effect on complement C8 and C9 uptake and lysis.
    Zalman LS; Müller-Eberhard H
    Mol Immunol; 1994 Mar; 31(4):301-5. PubMed ID: 8139583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the mechanism of cell membrane damage by complement: evidence on insertion of polypeptide chains from C8 and C9 into the lipid bilayer of erythrocytes.
    Hammer CH; Shin ML; Abramovitz AS; Mayer MM
    J Immunol; 1977 Jul; 119(1):1-8. PubMed ID: 559700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and antigenic similarities between a 94-kD protein of Schistosoma mansoni (SCIP-1) and human CD59.
    Parizade M; Arnon R; Lachmann PJ; Fishelson Z
    J Exp Med; 1994 May; 179(5):1625-36. PubMed ID: 7513011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.